Structure-Activity Relationship and Pharmacokinetic Studies of 1,5-Diheteroarylpenta-1,4-dien-3-ones: A Class of Promising Curcumin-Based Anticancer Agents

Journal of Medicinal Chemistry

Volumn 58, Issue 11, 2015, Pages 4713-4726

  Wang, Rubing ^a   Chen, Chengsheng ^a   Zhang, Xiaojie ^a   Zhang, Changde ^b   Zhong, Qiu ^b   Chen, Guanglin ^a   Zhang, Qiang ^b   Zheng, Shilong ^b   Wang, Guangdi ^b   Chen, Qiao Hong ^a  

^a CALIFORNIA STATE UNIVERSITY   (United States)

^b XAVIER UNIVERSITY OF LOUISIANA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,5 BIS(1 BUTYL 1H BENZO[D]IMIDAZOL 2 YL)PENTA 1,4 DIEN 3 ONE; 1,5 BIS(1 BUTYL 1H IMIDAZOL 2 YL)PENTA 1,4 DIEN 3 ONE; 1,5 BIS(1 ETHYL 1H BENZO[D]IMIDAZOL 2 YL)PENTA 1,4 DIEN 3 ONE; 1,5 BIS(1 ETHYL 1H IMIDAZOL 2 YL)PENTA 1,4 DIEN 3 ONE; 1,5 BIS(1 HEXYL 1H BENZO[D]IMIDAZOL 2 YL)PENTA 1,4 DIEN 3 ONE; 1,5 BIS(1 HEXYL 1H IMIDAZOL 2 YL)PENTA 1,4 DIEN 3 ONE; 1,5 BIS(1 ISOBUTYL 1H BENZO[D]IMIDAZOL 2 YL)PENTA 1,4 DIEN 3 ONE; 1,5 BIS(1 ISOPENTYL 1H BENZO[D]IMIDAZOL 2 YL)PENTA 1,4 DIEN 3 ONE; 1,5 BIS(1 ISOPENTYL 1H IMIDAZOL 2 YL)PENTA 1,4 DIEN 3 ONE; 1,5 BIS(1 ISOPROPYL 1H BENZO[D]IMIDAZOL 2 YL)PENTA 1,4 DIEN 3 ONE; 1,5 BIS(1 METHYL 1H BENZO[D]IMIDAZOL 2 YL)PENTA 1,4 DIEN 3 ONE; 1,5 BIS(1 PENTYL 1H BENZO[D]IMIDAZOL 2 YL)PENTA 1,4 DIEN 3 ONE; 1,5 BIS(1 PENTYL 1H IMIDAZOL 2 YL)PENTA 1,4 DIEN 3 ONE; 1,5 BIS(1 PROPYL 1H BENZO[D]IMIDAZOL 2 YL)PENTA 1,4 DIEN 3 ONE; 1,5 BIS(1 PROPYL 1H IMIDAZOL 2 YL)PENTA 1,4 DIEN 3 ONE; 1,5 BIS(1- SOPENTYL 1H IMIDAZOL 2 YL)PENTA 1,4 DIEN 3 ONE; 1,5 BIS(3 FLUOROPYRIDIN 4 YL)PENTA 1,4 DIEN 3 ONE; 1,5 BIS(4 BROMO 1 METHYL 1H PYRAZOL 3 YL)PENTA 1,4 DIEN 3 ONE; 1,5 BIS(4 METHYLTHIAZOL 2 YL)PENTA 1,4 DIEN 3 ONE; 1,5 BIS(6 METHYLPYRIDIN 2 YL)PENTA 1,4 DIEN 3 ONE; 1,5 BIS[1 (3 METHYLBUT 2 EN 1 YL) 1H IMIDAZOL 2 YL]PENTA 1,4 DIEN 3 ONE; 1,5 BIS[1 (PENTAN 2 YL) 1H BENZO[D]IMIDAZOL 2 YL]PENTA 1,4 DIEN 3 ONE; 1,5 BIS[1 (PENTAN 2 YL) 1H IMIDAZOL 2 YL]PENTA 1,4 DIEN 3 ONE; 1,5 BIS[1 (PENTAN 3 YL) 1H BENZO[D]IMIDAZOL 2 YL]PENTA 1,4 DIEN 3 ONE; 1,5 BIS[1 (PENTAN 3 YL) 1H IMIDAZOL 2 YL]PENTA 1,4 DIEN 3 ONE; 1,5 BIS[1 (SEC BUTYL) 1H BENZO[D]IMIDAZOL 2 YL]PENTA 1,4 DIEN 3 ONE; 1,5 BIS[2 METHYL 4 (TRIFLUOROMETHYL)THIAZOL 5 YL]PENTA 1,4 DIEN 3 ONE; 1,5 DI(QUINOLIN 4 YL)PENTA 1,4 DIEN 3 ONE; CURCUMIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; 1,5-BIS(2-METHYL-4-(TRIFLUOROMETHYL)THIAZOL-5-YL)PENTA-1,4-DIEN-3-ONE; ALKANONE; ANTINEOPLASTIC AGENT; THIAZOLE DERIVATIVE;

ALDOL REACTION; ALKYLATION; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CERVICAL CANCER CELL LINE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG POTENCY; DRUG SOLUBILITY; DRUG SYNTHESIS; FEMALE; HELA CELL LINE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HORNER WADSWORTH EMMONS REACTION; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; IN VIVO STUDY; LNCAP CELL LINE; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PROSTATE CANCER; PROSTATE CANCER CELL LINE; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; UTERINE CERVIX CANCER; WST-1 ASSAY; ANIMAL; C57BL MOUSE; CELL PROLIFERATION; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; PATHOLOGY; PROSTATIC NEOPLASMS; TISSUE DISTRIBUTION; TUMOR CELL CULTURE; UTERINE CERVICAL NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CURCUMIN; DRUG DESIGN; FEMALE; HUMANS; MALE; MICE; MICE, INBRED C57BL; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PENTANONES; PROSTATIC NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP; TANDEM MASS SPECTROMETRY; THIAZOLES; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED; UTERINE CERVICAL NEOPLASMS;

EID: 84935883110     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b00470     Document Type: Article

References (37)

1. Parkin, D. M.; Brag, F.; Ferlay, J.; Pisani, P. Global cancer statistics Cancer J. Clin. 2005, 55, 74 - 108
2. Teiten, M.-H.; Gaascht, F.; Eifes, S.; Dicato, M.; Diederich, M. Chemopreventive potential of curcumin in prostate cancer Genes Nutr. 2010, 5, 61 - 74
3. Aggarwal, B. B. Prostate cancer and curcumin: add spice to your life Cancer Biol. Ther. 2008, 7, 1436 - 1440
4. Dorai, T.; Gehani, N.; Katz, A. Therapeutic potential of curcumin in human prostate cancer. I. Curcumin induces apoptosis in both androgen-dependent and androgen-independent prostate cancer cells Prostate Cancer Prostatic Dis. 2000, 3, 84 - 93
5. Toennesen, H. H.; Karlsen, J.; Mostad, A. Structural studies of curcuminoids. I. The crystal structure of curcumin Acta Chem. Scand., Ser. B 1982, B36, 475 - 479
6. Garcea, G.; Jones, D. J. L.; Singh, R.; Dennison, A. R.; Farmer, P. B.; Sharma, R. A.; Steward, W. P.; Gescher, A. J.; Berry, D. P. Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration Br. J. Cancer 2004, 90, 1011 - 1015
7. Agrawal, D. K.; Mishra, P. K. Curcumin and its analogues: potential anticancer agents Med. Res. Rev. 2010, 30, 818 - 860
8. Basnet, P.; Skalko-Basnet, N. Curcumin: an anti-inflammatory molecule from a curry spice on the path to cancer treatment Molecules 2011, 16, 4567 - 4598
9. Sonn, G. A.; Aronson, W.; Litwin, M. S. Impact of diet on prostate cancer: a review Prostate Cancer Prostatic Dis. 2005, 8, 304 - 310
10. Mimeault, M.; Batra, S. K. Potential applications of curcumin and its novel synthetic analogs and nanotechnology-based formulations in cancer prevention and therapy Chin. Med. 2011, 6, 31
11. Nambiar, D.; Singh, R. P. Advances in prostate pancer chemoprevention: a translational perspective Nutr. Cancer 2013, 65 (Suppl. 1) 12 - 25
12. Hajare, R. A.; Bajad, S. A.; Parwani, K. S.; Chandekar, N. A.; Chandewar, A. V. Therapeutic potential of curcumin in prostate cancer Pharma Rev. 2009, 7, 123 - 124
13. Kurien, B. T.; Scofield, R. H. Curry spice curcumin and prostate cancer Mol. Nutr. Food Res. 2009, 53, 939 - 940
14. Gupta, S. C.; Patchva, S.; Aggarwal, B. B. Therapeutic roles of curcumin: lessons learned from clinical trials AAPS J. 2013, 15, 195 - 218
15. Cretu, E.; Trifan, A.; Vasincu, A.; Miron, A. Plant-derived anticancer agents-curcumin in cancer prevention and treatment Rev. Med.-Chir. Soc. Med. Nat. Iasi 2012, 116, 1223 - 1229
16. Chen, Q.-H. Curcumin-based anti-prostate cancer agents Anti-Cancer Agents Med. Chem. 2015, 15, 138 - 156
17. Lin, L.; Hutzen, B.; Ball, S.; Foust, E.; Sobo, M.; Deangelis, S.; Pandit, B.; Friedman, L.; Li, C.; Li, P. K.; Fuchs, J.; Lin, J. New curcumin analogues exhibit enhanced growth-suppressive activity and inhibit AKT and signal transducer and activator of transcription 3 phosphorylation on breast and prostate cancer cells Cancer Sci. 2009, 100, 1719 - 1727
18. Samaan, N.; Zhong, Q.; Fernandez, J.; Chen, G.; Hussain, A. M.; Zheng, S.; Wang, G.; Chen, Q.-H. Design, synthesis, and evaluation of novel heteroaromatic analogs of curcumin as anti-cancer agents Eur. J. Med. Chem. 2014, 75, 123 - 131
19. Baell, J. B.; Holloway, G. A. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays J. Med. Chem. 2010, 53, 2719 - 2740
20. Baell, J. B. Screening-based translation of public research encounters painful problems ACS Med. Chem. Lett. 2015, 6, 229 - 234
21. Cao, B.; Wang, Y.; Ding, K.; Neamati, N.; Long, Y.-Q. Synthesis of the pyridinyl analogues of dibenzylideneacetone (pyr-dba) via an improved Claisen-Schmidt condensation, displaying diverse biological activities as curcumin analogues Org. Biomol. Chem. 2012, 10, 1239 - 1245
22. Sehnal, P.; Taghzouti, H.; Fairlamb, I. J. S.; Jutand, A.; Lee, A. F.; Whitwood, A. C. Heteroaromatic analogues of dibenzylideneacetone (dba) and Pd02(het-dba)3 complexes: effect of a thienyl moiety on the reactivity of Pd0(η2-thn-dba)(PPh3)2/Pd0(PPh3)2 (n=1 or 2) and Pd0 (η2-thn-dba)(dppe)/Pd0(dppe) in oxidative addition reactions with iodobenzene Organometallics 2009, 28, 824 - 829
23. Corbel, B.; Medinger, L.; Haelters, J. P.; Sturtz, G. An efficient synthesis of dialkyl 2-oxoalkanephosphonates and diphenyl-2-oxoalkylphosphine oxides from 1-chloralkyl ketones Synthesis 1985, 1048 - 105185
24. Seto, M.; Miyamoto, N.; Aikawa, K.; Aramaki, Y.; Kanzaki, N.; Iizawa, Y.; Baba, M.; Shiraishi, M. Orally active CCR5 antagonists as anti-HIV-1 agents. Part 3: synthesis and biological activities of 1-benzazepine derivatives containing a sulfoxide moiety Bioorg. Med. Chem. 2005, 13, 363 - 386
25. Woo, H. B.; Eom, Y. W.; Park, K. S.; Ham, J.; Ahn, C. M.; Lee, S. Synthesis of substituted benzimidazolyl curcumin mimics and their anticancer activity Bioorg. Med. Chem. Lett. 2012, 22, 933 - 936
26. Valdez-Padilla, D.; Rodriguez-Morales, S.; Hernandez-Campos, A.; Hernandez-Luis, F.; Yepez-Mulia, L.; Tapia-Contreras, A.; Castillo, R. Synthesis and antiprotozoal activity of novel 1-methylbenzimidazole derivatives Bioorg. Med. Chem. 2009, 17, 1724 - 1730
27. Campaigne, E.; Thompson, R. L.; Van Werth, J. E. Some heterocyclic aldehyde thiosemicarbazones possing anti-viral activity J. Med. Chem. 1959, 1, 577 - 599
28. Kaighn, M. E.; Narayan, K. S.; Ohnuki, Y.; Lechner, J. F.; Jones, L. W. Establishment and characterization of a human prostatic carcinoma cell line (PC-3) Invest. Urol. 1979, 17, 16 - 23
29. Stone, K. R.; Mickey, D. D.; Wunderli, H.; Michey, G. H.; Paulson, D. F. Isolation of a human prostate carcinoma cell line (DU145) Int. J. Cancer. 1978, 21, 274 - 281
30. Horoszewicz, J. S.; Leong, S. S.; Kawinski, E.; Karr, J. P.; Rosenthal, H.; Chu, T. M.; Mirand, E. A.; Murphy, G. G. P. LNCaP model of human prostatic carcinoma Cancer Res. 1983, 43, 1809 - 1818
31. Garcea, G.; Jones, D. J.; Singh, R.; Dennison, A. R.; Farmer, P. B.; Sharma, R. A.; Steward, W. P.; Gescher, A. J.; Berry, D. P. Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration Br. J. Cancer 2004, 90, 1011 - 1015
32. Marczylo, T. H.; Verschoyle, R. D.; Cooke, D. N.; Morazzoni, P.; Steward, W. P.; Gescher, A. J. Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholine Cancer Chemother. Pharmacol. 2007, 60, 171 - 177
33. Sharma, R. A.; McLelland, H. R.; Hill, K. A.; Ireson, C. R.; Euden, S. A.; Manson, M. M.; Pirmohamed, M.; Marnett, L. J.; Gescher, A. J.; Steward, W. P. Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer Clin. Cancer Res. 2001, 7, 1894 - 1900
34. Kanai, M. Therapeutic applications of curcumin for patients with pancreatic cancer World J. Gastroenterol. 2014, 28, 9384 - 9391
35. Lao, C. D.; Ruffin, M. T.; Normolle, D.; Heath, D. D.; Murray, S. I.; Bailey, J. M.; Boggs, M. E.; Crowell, J.; Rock, C. L.; Brenner, D. E. Dose escalation of a curcuminoid formulation BMC Complementary Altern. Med. 2006, 6, 10
36. Wichitnithad, W.; Nimmannit, U.; Wacharasindhu, S.; Rojsitthisak, P. Synthesis, characterization and biological evaluation of succinate prodrugs of curcuminoids for colon cancer treatment Molecules 2011, 16, 1888 - 1900
37. Lee, Y.-Z.; Yang, C.-W.; Hsu, H.-Y.; Qiu, Y.-Q.; Yeh, T.-K.; Chang, H.-Y.; Chao, Y.-S.; Lee, S.-J. Synthesis and biological evaluation of tylophorine-derived dibenzoquinolines as orally active agents: exploration of the role of tylophorine E ring on biological activity J. Med. Chem. 2012, 55, 10363 - 10377